Skip Navigation LinksHome   >   About   >   ESG

Environmental, Social and Governance

Oxford Cannabinoid Technologies (OCT or “The Company”) is strongly committed to generate sustainable financial returns by integrating responsible investment and operational decisions with Environmental, Social and Governance Considerations.

Work Environment and General Policy

Equal opportunities

The Company is an equal opportunity organisation.

As scientists, we believe genetics and epigenetics define how our body works and not who we are.

Everyone at OCT is committed to a policy guaranteeing that, within the Company and across academic and business partners, behaviours are aligned to strong responsible governance considerations. We ensure that people receive equal treatment, regardless of gender, gender-identity, age, disability, religion, belief, political views, sexual orientation, marital status, nationality or race, physical or mental health. We apply these principles to all areas of our business including, but not limited to, remuneration, recruitment, placement, role assignment, training, mentoring, promotion, life/work balance, disciplinary measures, termination, and redundancy.

Diversity

OCT is committed to creating a diverse environment where the rights and differences of everyone directly or indirectly operating within the Company are valued as a way to enrich the potential of our teams and our people.

Discrimination and Harassment

OCT prohibits any form of bullying and discrimination, including (but not exhaustively) sexual and non-sexual harassment, direct or indirect discrimination, and victimisation against other people internal or external to OCT, including current and former employees, job applicants, clients, customers, suppliers, and visitors. These considerations are applied inside and outside the workplace (e.g., when dealing with suppliers, collaborators, patients), and on work-related trips or events including social events. In addition, OCT ensures that all its associates and collaborators employ the same strict approach by promoting and enabling similar policies.

Research Animal Care and Welfare

At Oxford Cannabinoid Technologies (OCT or “The Company”) we research, develop and manufacture innovative medicinal products. Due to scientific and regulatory reasons, animal studies represent a small but crucial part of our commitment to deliver safe and efficacious therapies to benefit patients, their families and their communities.

The Company is actively engaging with partners which develop and validate experimental methods that can provide alternatives to the use of animals in research. However, even though OCT, its scientific and business partners, and affiliates are eagerly using cutting-edge technology and coordinating efforts with legislators, regulators, and scientific institutions to completely eliminate animal studies from their efforts, at present this is not possible, either due to lack of suitable alternatives or because animal studies are required by regulatory authorities.

The Company ensures that any collaborator is strictly following international and local legislation and regulatory guidelines and consequently will not perform procedures which are deemed unethical or illegal under The Animal Welfare Act 2006. OCT enforces a voluntary ban on the use of great apes (i.e., chimpanzees) in research even in countries where it is legal to do so.

At OCT we recognise that it is our moral and ethical responsibility to treat all animals respectfully, while striving to minimise pain or distress and to avoid it completely when it is not necessary. This moral imperative applies even more so to animals whose utilisation is aimed to bring benefit to human health. To such avail, OCT is committed to follow high-standard, internationally recognised practices focusing on the considerations regarding the replacement of animals when possible and/or acceptable, the reduction of the numbers of experiments and of animals required by each experiment, and the minimisation of pain and distress by means of refinement of animal studies procedures. (“The 3Rs”).

All animals used in OCT studies are specifically bred for research. In addition, all animal facilities where animals are bred, housed, or undergo procedure are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (i.e., AAALAC-accredited) or is in the process of first accreditation and undergo regular visits by AAALAC. This ensures that all animal staff are competent, trained, continuously educated and assessed. OCT ensures that qualified veterinarians are available at all times for advice and help in the care of animals and in the conduct and termination of the research.

At OCT we do not work with or test cosmetics, food, or drink supplements.

Environment, Health and Safety (EHS)

OCT gives great importance to the wellbeing and health and safety of its employees and of all the people supporting the Company efforts outside its organisation.

In addition, OCT is strongly committed to reducing the potential impact of its activities in the environment and to conserving natural resources by ensuring that its facilities and the facilities of academic and contracted collaborators are operated to optimise energy usage, to minimise waste production, and to protect nature and people alike.

OCT uses hazardous or potentially hazardous chemical and biological entities, at every stage of its research and development. These entities are necessary to allow OCT to carry out research to identify the causes and the solutions to diseases and discover new medicines. This is particularly relevant during manufacturing of the active pharmaceutical ingredients (APIs) and their final formulation into the potential medicine, together with excipients and vehicles. Sometimes, the potential hazards are intrinsic with their mechanisms of action rendering them a useful therapeutic tool.

The Company is therefore committed to ensure that hazardous chemicals and biologicals are acquired, stored, transferred, modified, handled, and disposed of in a way that minimises any potential adverse effects to human health and to the environment. Their use must be based on both an understanding of the hazards they present and on the corresponding controls aimed at managing the risk of exposure.

OCT complies with the local and national guidelines in all matters of EHS. To such avail the Company ensures its employees are knowledgeable, and trained where necessary, to identify and prevent risks and hazards associated with the use of substances hazardous to health and with any other aspect of its core business activities. In addition, OCT cooperates with its partners to make sure safe systems of work, local procedures, risk assessment, and relevant and continuous training are part of their standard operating procedures and that they take all reasonable steps to ensure all accidents, incidents, near-misses, and safety observations are reported and investigated in a timely fashion and that corrective measures are swiftly implemented.